Bortezomib-based treatment can improve factor X activity in immunoglobulin light-chain amyloidosis with factor X deficiency

Amyloid. 2019 Dec;26(4):255-256. doi: 10.1080/13506129.2019.1663815. Epub 2019 Sep 17.

Authors

Xia Wu¹, Hui-Lei Miao¹, Tie-Nan Zhu¹, Jun Feng¹, Lu Zhang¹, Yue-Ying Mao¹, Dao-Bin Zhou¹, Xin-Xin Cao¹, Jian Li¹

Affiliation

¹ Department of Hematology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing , PR China.

PMID: 31526149
DOI: 10.1080/13506129.2019.1663815

No abstract available

MeSH terms

Adult
Aged
Bortezomib / administration & dosage*
Factor X / metabolism*
Factor X Deficiency* / blood
Factor X Deficiency* / complications
Factor X Deficiency* / drug therapy
Female
Humans
Immunoglobulin Light-chain Amyloidosis* / blood
Immunoglobulin Light-chain Amyloidosis* / complications
Immunoglobulin Light-chain Amyloidosis* / drug therapy
Male
Middle Aged
Retrospective Studies

Substances

Bortezomib
Factor X